Financial Review: Catalent (CTLT) & Its Peers
Catalent (NYSE: CTLT) is one of 105 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Catalent to related businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Institutional and Insider Ownership
99.5% of Catalent shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of Catalent shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Catalent has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Catalent’s peers have a beta of 34.13, meaning that their average stock price is 3,313% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Catalent and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalent presently has a consensus target price of $43.71, indicating a potential upside of 10.06%. As a group, “Pharmaceuticals” companies have a potential upside of 24.39%. Given Catalent’s peers higher possible upside, analysts plainly believe Catalent has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares Catalent and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Catalent||$2.08 billion||$109.80 million||45.66|
|Catalent Competitors||$8.17 billion||$1.09 billion||144.00|
Catalent’s peers have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Catalent and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Catalent peers beat Catalent on 7 of the 13 factors compared.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.